scholarly journals Development of Biological Prognostic Score Versions 2 and 3 for Advanced Cancer Patients and a Prospective Study on the Prediction Accuracy: Comparison with the Palliative Prognostic Index

2017 ◽  
Vol 12 (1) ◽  
pp. 140-148 ◽  
Author(s):  
Masahide Omichi ◽  
Saya Konoike ◽  
Yuji Yamada ◽  
Akira Takahashi ◽  
Masahiro Narita ◽  
...  
2014 ◽  
Vol 28 (7) ◽  
pp. 959-964 ◽  
Author(s):  
Matteo Moroni ◽  
Donato Zocchi ◽  
Deborah Bolognesi ◽  
Amy Abernethy ◽  
Roberto Rondelli ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Michele Moschetta ◽  
Mario Uccello ◽  
Benjamin Kasenda ◽  
Gabriel Mak ◽  
Anissa McClelland ◽  
...  

Introduction. Baseline neutrophil-to-lymphocyte ratio (NLR) has been repeatedly reported as a significant prognostic factor in advanced cancer patients. We explored whether changes in NLR may predict outcome of advanced cancer patients enrolled into phase 1 trials and treated with PD-1/PD-L1 inhibitors. Patients and Methods. Advanced cancer patients enrolled into phase 1 trials between September 2013 and May 2016 and treated with anti-PD-1/PD-L1 agents were included in this retrospective study. NLR was calculated at baseline and after 2 cycles of treatment. Royal Marsden Hospital (RMH) prognostic score and Eastern Cooperative Group (ECOG) performance status (PS) were determined at baseline. Kaplan-Meier estimation and Cox regression analyses were used to assess the impact of NLR dynamics on PFS. Results. Among the 55 patients eligible, 26 (47%) were treated with anti-PD-L1 monotherapy, 22 (40%) received single agent anti-PD-1, and 7 (13%) were given a tyrosine kinase inhibitor (TKI) plus a PD-1 inhibitor. Neither ECOG PS nor RMH prognostic score was significantly associated with PFS in our cohort, whereas changes in NLR significantly impacted on PFS. Conclusion. Changes in the NLR may be a useful predicting factor in advanced cancer patients treated with anti-PD-1/PD-L1 agents. Further prospective trials are needed to verify these findings.


2016 ◽  
Vol 52 (3) ◽  
pp. 420-427 ◽  
Author(s):  
Hyun Jung Jho ◽  
Sang-Yeon Suh ◽  
Seok-Joon Yoon ◽  
Sanghee Shiny Lee ◽  
Hong-Yup Ahn ◽  
...  

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23007-e23007
Author(s):  
Lorena Ostios-García ◽  
Jesus Miranda Poma ◽  
Darío Sánchez Cabrero ◽  
Laura Gutiérrez Sainz ◽  
Julia Villamayor Sánchez ◽  
...  

e23007 Background: The aim of our study was to determine if an unscheduled hospitalization in advanced cancer patients is a good time for palliative care referrals, and if this indicator could be improved with some other prognostic score. Methods: We conducted a retrospective study, which included all patients with unscheduled hospitalization in the medical oncology service from January 2011 to December 2013. In order to improve the accuracy of the analysis we considered only first admissions of each patient. We excluded patients with scheduled and unindicated hospitalization. The main variable was survival after an unscheduled hospitalization. We collected the following variables: demographic (age, sex, date of birth, date of death and place of death), tumor type, clinical variables (reason for admission, date of hospitalization, assessment by the palliative care unit during hospitalization, date of last chemotherapy and ECOG), analytical variables (albumin, lymphocytes and lactate dehydrogenase) and a prognostic nomogram developed by our team. Results: Inclusion criteria were met by 1,180 patients. Table summarizes the main sociodemographic characteristics, the type of tumor, and the functional status of patients according to the ECOG scale. After two years of follow-up, 816 (69%) patients had died. The median overall survival was 188 days (161-214). Patients with breast and gynecological cancer had the longest survival, while patients with melanoma, gastric cancer, lung cancer, and pancreatic cancer had the poorest survival. 676 patients (58%) were readmitted during the following year. Readmissions meant a significant decrease of survival. The stage of the oncological disease and performance status measured by ECOG had a clear relationship with survival time. Prognostic nomogram showed high accuracy to predict the probability of survival. Median survival for different quartile was respectively: 348, 139, 68 and 31 days (p < 0´000). Conclusions: The median survival of patients after an unscheduled hospitalization was around 6 months. Been admitted seems a good indicator to introduce specific palliative care. The use of other prognostic scores, as a prognostic nomogram, could help to select patient’ groups with poorer survivals. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document